MRM

MEDIROM Healthcare Technologies Inc. (MRM) PESTLE Analysis Analysis (2026)

Invetso Score: 4.8/10 — Balanced · Last Updated: 2026-09-01

Political

No major political or regulatory catalyst is evident from the current data set.

The company remains exposed to general policy and public-sector spending conditions, but no month-over-month change is indicated.

Economic

Revenue and valuation remain highly cyclical, with EV/Sales at 0.81x and no fresh news suggesting a demand inflection.

Profitability and cash generation are still weak, with negative EBIT margin (-19.8%) and negative free cash flow yield (-48.8%).

Social

No new customer, brand, or audience-trend developments were reported this month.

The business still appears dependent on stable client engagement and retention, but there is no fresh evidence of a shift in social demand.

Technological

No new product, platform, or technology investment news was provided this month.

Operating efficiency remains pressured, with a long cash conversion cycle of 313 days and weak operating cash flow metrics.

Legal

No new litigation, compliance, or contract-risk headlines were reported this month.

Interest coverage remains negative, which can heighten covenant and creditor sensitivity even without a new legal event.

Environmental

No material environmental disclosure or sustainability-related news was provided this month.

There is no evidence of a change in environmental exposure from the fresh data.

Overall Score

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on MEDIROM Healthcare Technologies Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →